






This center treats substance use disorders and co-occurring mental health conditions. Your treatment plan addresses each condition at once with personalized, compassionate care for comprehensive healing.
Offering intensive care with 24/7 monitoring, residential treatment is typically 30 days and can cover multiple levels of care. Length can range from 14 to 90 days typically.
This provider hasn't verified their profile's information. Are you the owner of this center? Claim your listing to better manage your presence on Recovery.com.
This center treats substance use disorders and co-occurring mental health conditions. Your treatment plan addresses each condition at once with personalized, compassionate care for comprehensive healing.
Offering intensive care with 24/7 monitoring, residential treatment is typically 30 days and can cover multiple levels of care. Length can range from 14 to 90 days typically.
This center accepts insurance, exact cost can vary depending on your plan and deductible.
New Vista's residential treatment at The Schwartz Center supports adults with opioid addiction, including those on or starting medication, and co-occurring mental health disorders. Their short-term 28-day program offers an individualized, non-judgmental environment with separate, distraction-free spaces for men and women, focused on a clear path to recovery.
The program's approach centers on individual needs, providing a structured daily schedule with group and individual counseling, family therapy, and educational sessions. Patients benefit by building a strong recovery foundation, learning about addiction, and developing essential coping and daily living skills crucial for a life free from substance use.
The residential setting at The Schwartz Center offers separate living spaces, with 12 beds for men and 12 for women. Their program includes transportation for essential activities like court or medical appointments. After residential treatment, they offer intensive outpatient programs (IOP) and outpatient counseling, which provide skill-building, relapse prevention, coping strategies, and case management to improve recovery chances.
This center treats substance use disorders and co-occurring mental health conditions. Your treatment plan addresses each condition at once with personalized, compassionate care for comprehensive healing.
The Joint Commission accreditation is a voluntary, objective process that evaluates and accredits healthcare organizations (like treatment centers) based on performance standards designed to improve quality and safety for patients. To be accredited means the treatment center has been found to meet the Commission's standards for quality and safety in patient care.

Medication-Assisted Treatment (MAT) is an evidence-based approach that pairs FDA-approved medications with counseling to treat addiction. The medications are used to reduce cravings, ease withdrawal symptoms, or block the effects of substances. More about MAT

Dolophine®, Methadose®
Methadone is a full opioid agonist, meaning it activates opioid receptors in the brain to produce effects like pain relief and euphoria. It is longer acting than many other opioids, making it useful in medication-assisted treatment for opioid use disorder.
It reduces withdrawal symptoms and cravings by occupying opioid receptors without causing intense highs. Because it is a full agonist, it must be used carefully to avoid overdose, but it is highly effective when taken as prescribed within a structured program.

Vivitrol®, Revia®
Naltrexone is an opioid antagonist, meaning it blocks opioid receptors in the brain and prevents opioids from producing effects like euphoria or sedation. It is used to treat both opioid and alcohol use disorders, but does not cause physical dependence or withdrawal.
It helps reduce cravings and the rewarding effects of opioids or alcohol, supporting long-term recovery. Because it blocks opioid effects, it should only be started after a person has fully detoxed from opioids to avoid triggering withdrawal.

Suboxone®, Subutex®, Sublocade®, Zubsolv®
Buprenorphine is a partial opioid agonist used to treat opioid use disorder. It activates opioid receptors to reduce cravings and withdrawal but has a ceiling effect, meaning it produces less euphoria and respiratory depression than full opioids.
Buprenorphine binds tightly to opioid receptors, blocking other opioids from attaching and reducing the risk of misuse. It's often combined with naloxone (as in Suboxone®) to discourage injection misuse and is available in daily or monthly forms.